In fresh blow, Roche shutters HIV research program

In another big blow to the AIDS research field, pharma giant Roche is dumping its R&D work in the field. The Financial Times reports that disappointing clinical results had persuaded Roche to shutter programs focused on two different ways to attack HIV. Roche has committed its research work to new programs that promise to offer a significant advance on existing therapies.

"While we had initially been hopeful about their potential, we now have concluded that none would provide a true incremental benefit for patients compared to medicines currently on the market," said Jenny Edge-Dallas, global leader for Roche's HIV Franchise.

- read the report from the Financial Times

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.